Six-Month Real-World Data in Macular Edema Due to Retinal Vein Occlusion Treated with Faricimab: Swiss Retina Research Network Report

Macular Diseases

First-year real-world outcomes of faricimab in clinically significant diabetic macular oedema: a Swiss retina research network report

BMJ Open Ophthalmol

Saad A, Plasencia C, Garweg J, Pfister IB, Munk MR, Eandi CM, Zweifel SA, Grimaldi G, Bartolomeo N, Stillenmunkes R, Schild C, Cattaneo J, Gabathuler F, Menghini M, Ambersin A, Froehlich J, Artemiev D, Weinberger A, Mohamed H, Somfai GM, Hatz K

doi: 10.1136/bmjophth-2025-002467

Macular DiseasesRetinal Diseases

One-Year Outcomes of Faricimab in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report

Ophthalmol Ther

Tillmann A, Stillenmunkes R, Garweg JG, Cattaneo J, Bartolomeo N, Grimaldi G, Spitznagel T, De Oliveira Figueiredo EC, Ambresin A, Menghini M, Somfai GM, Zweifel S, Fröhlich J, Artemiev D, Ebneter A, Hatz K, Weinberger A, Pfister IB, Schild C, Eandi C, Munk MR, Swiss Retina Research Network

doi: 10.1007/s40123-025-01252-6

Macular Diseases

One-Year Real-World Outcomes of Switching to Aflibercept 8 mg in Eyes with Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report

Ophthalmol Ther

Kitay AM, Tillmann A, Pfister I, Schild C, Bonanata M, Heck K, Spitznagel T, Gabathuler F, Bartolomeo N, Magnin S, Löliger J, Munk MR, Menghini M, Hatz K, Somfai GM, Zweifel S, Ambresin A, Eandi CM, Feltgen N, Weinberger A, Garweg JG, Kurz-Levin MM

doi: 10.1007/s40123-026-01344-x

Macular Diseases

One-Year Real-World Outcomes of Aflibercept 8 mg in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report

Ophthalmol Ther

Grimaldi G, Bartolomeo N, Garweg JG, Pfister IB, Schild C, Peyla A, Tillmann A, De Oliveira Figueiredo EC, Spitznagel T, Kitay AM, Gabathuler F, Zweifel S, Kurz-Levin MM, Ebneter A, Somfai GM, Eandi CM, Munk MR, Ambresin A, Menghini M

doi: 10.1007/s40123-025-01305-w

Macular Diseases

Twelve-Month Outcomes Using Aflibercept 8 mg in Treatment-Naïve and Pretreated Diabetic Macular Edema: A Swiss Retina Research Network Report

Ophthalmol Sci

Spindler J, Artemiev D, Pfister IB, Schild C, Tillmann A, Heck K, Gabathuler F, Ruscitti L, Spitznagel T, Kitsos-Kalyvianakis K, Munk MR, Hatz K, Zweifel SA, Grimaldi G, Somfai GM, Ambresin A, Weinberger A, Eandi CM, Feltgen N, Kitay A, Ebneter A, Garweg JG

doi: 10.1016/j.xops.2026.101087

Macular DiseasesRetinal Diseases

Visual outcomes and anatomical biomarkers of Faricimab for diabetic macular edema in the J-CREST real-world comparison of naïve and treated eyes

Sci Rep

Murao F, Yanai R, Kusuhara S, Abe Y, Shimura M, Ohara H, Terasaki H, Sugimoto M, Matsubara H, Hirano Y, Kinoshita T, Tsujinaka H, Seki K, Iwase T, Mitamura Y, J-CREST

doi: 10.1038/s41598-025-20300-6

Macular Diseases

Aflibercept 24-Month Outcomes in Diabetic Macular Edema With and Without Prior Macular Laser Therapy: Data from the Fight Retinal Blindness! Registry

Ophthalmol Ther

Timoceanu L, Steinmann S, Gillies MC, Barthelmes D

doi: 10.1007/s40123-026-01449-3

Retinal DiseasesFurther Publications

Real-world retinal vasculitis events reported with FDA-approved intravitreal anti-VEGF and complement inhibitor agents: an analysis of FAERS data

Retina

Chhablani J, Nayaka A, Sadeghi E, B G

doi: 10.1097/IAE.0000000000004980

Retinal Diseases

Real-World Insights on Switching Aflibercept Dosage for Enhanced Outcomes in Retinal Vein Occlusion (RISE-RVO): visual, anatomical and durability outcomes

Br J Ophthalmol

Nguyen CT, Lassen RKB, Mæng MO, Lee C, Subhi Y, Vorum H, Wykoff CC, Ørskov M, Cehofski LJ

doi: 10.1136/bjo-2025-329273

Related content

First-year real-world outcomes of faricimab in clinically significant diabetic macular oedema: a Swiss retina research network report

One-Year Outcomes of Faricimab in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report

One-Year Real-World Outcomes of Switching to Aflibercept 8 mg in Eyes with Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report

One-Year Real-World Outcomes of Aflibercept 8 mg in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report

Twelve-Month Outcomes Using Aflibercept 8 mg in Treatment-Naïve and Pretreated Diabetic Macular Edema: A Swiss Retina Research Network Report

Visual outcomes and anatomical biomarkers of Faricimab for diabetic macular edema in the J-CREST real-world comparison of naïve and treated eyes

Aflibercept 24-Month Outcomes in Diabetic Macular Edema With and Without Prior Macular Laser Therapy: Data from the Fight Retinal Blindness! Registry

Real-world retinal vasculitis events reported with FDA-approved intravitreal anti-VEGF and complement inhibitor agents: an analysis of FAERS data

Real-World Insights on Switching Aflibercept Dosage for Enhanced Outcomes in Retinal Vein Occlusion (RISE-RVO): visual, anatomical and durability outcomes